These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 19035161)

  • 41. Two-year outcome of patients treated with sirolimus- versus paclitaxel-eluting stents in an unselected population with coronary artery disease (from the REWARDS Registry).
    Roy P; Bonello L; de Labriolle A; Okabe T; Pinto Slottow TL; Steinberg DH; Torguson R; Smith K; Xue Z; Satler LF; Kent KM; Suddath WO; Pichard AD; Waksman R
    Am J Cardiol; 2008 Aug; 102(3):292-7. PubMed ID: 18638589
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety and efficacy of everolimus-eluting stents versus paclitaxel-eluting stents in a diabetic population.
    Laynez A; Sardi G; Hauville C; Barbash IM; Pakala R; Torguson R; Xue Z; Satler LF; Pichard AD; Waksman R
    Catheter Cardiovasc Interv; 2013 Apr; 81(5):759-65. PubMed ID: 22488756
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-term clinical outcomes after bioabsorbable polymer- and durable polymer-based sirolimus-eluting stents implantation: two-year follow-up results from a large single-center database.
    Liu HB; Xu B; Yang YJ; Wang Y; Qin XW; Yao M; Wu YJ; Yuan JQ; Chen J; You SJ; Dai J; Ma WH; Li JJ; Qiao SB; Chen JL; Li W; Gao RL
    Chin Med J (Engl); 2009 Mar; 122(6):681-6. PubMed ID: 19323934
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Outcome of patients implanted with bioabsorbable polymer sirolimus-eluting stent (Excel) and the durable polymer sirolimus-eluting stent (Cypher)].
    GAO Z; YANG YJ; CHEN JL; Qiao SB; XU B; QIN XW; YAO M; LIU HB; WU YJ; YUAN JQ; CHEN J; YOU SJ; Li JJ; GAO RL
    Zhonghua Xin Xue Guan Bing Za Zhi; 2008 Dec; 36(12):1074-7. PubMed ID: 19134273
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment of coronary bifurcation lesions with drug-eluting stents: insights from the first phase of the prospective multicenter german drug-eluting stent registry.
    Abdel-Wahab M; Nienaber CA; Mostafa AE; Ferenc M; Silber S; Sabin G; Tebbe U; Akin I; Hochadel M; Senges J; Kuck KH; Richardt G;
    J Interv Cardiol; 2012 Aug; 25(4):344-52. PubMed ID: 22409587
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A patient-level pooled analysis assessing the impact of the SYNTAX (synergy between percutaneous coronary intervention with taxus and cardiac surgery) score on 1-year clinical outcomes in 6,508 patients enrolled in contemporary coronary stent trials.
    Garg S; Sarno G; Girasis C; Vranckx P; de Vries T; Swart M; Bressers M; Garcia-Garcia HM; van Es GA; Räber L; Campo G; Valgimigli M; Dawkins KD; Windecker S; Serruys PW
    JACC Cardiovasc Interv; 2011 Jun; 4(6):645-53. PubMed ID: 21700251
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Effects of sirolimus-eluting stent and the paclitaxel-eluting stent: a three-year follow-up study].
    Gao Z; Yang YJ; Chen JL; Qiao SB; Xu B; Qin XW; Yao M; Liu HB; Wu YJ; Yuan JQ; Chen J; You SJ; Li JJ; Gao RL
    Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(26):1811-4. PubMed ID: 19040014
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Serial intravascular ultrasound analysis of peri-stent remodeling and proximal and distal edge effects after sirolimus-eluting or paclitaxel-eluting stent implantation in patients with diabetes mellitus.
    Jensen LO; Maeng M; Mintz GS; Christiansen EH; Hansen KN; Galloe A; Kelbaek H; Lassen JF; Thuesen L; Thayssen P
    Am J Cardiol; 2009 Apr; 103(8):1083-8. PubMed ID: 19361594
    [TBL] [Abstract][Full Text] [Related]  

  • 49. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions.
    Grube E; Silber S; Hauptmann KE; Mueller R; Buellesfeld L; Gerckens U; Russell ME
    Circulation; 2003 Jan; 107(1):38-42. PubMed ID: 12515740
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cypher versus Taxus: the stent war.
    Shafiq N; Malhotra S; Pandhi P; Behl A; Sharma YP
    Expert Opin Investig Drugs; 2006 Dec; 15(12):1537-44. PubMed ID: 17107279
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety and feasibility of Bivalirudin with either Cypher and Taxus drug-eluting stent during percutaneous coronary intervention.
    Chieffo A; Melzi G; Rogacka R; Ferrari A; Airoldi F; Cosgrave J; Michev I; Montorfano M; Carlino M; Vitrella G; Biondi Zoccai G; Colombo A
    EuroIntervention; 2005 May; 1(1):70-4. PubMed ID: 19758880
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment of symptomatic coronary artery disease in patients with end-stage renal disease on hemodialysis with paclitaxel-eluting TAXUS stent.
    Wiernek SL; Kiesz RS; Wiernek BK; Buszman PP; Janas A; Martin JL; Trela B; Szewc RG; Buszman PE
    Hemodial Int; 2015 Jul; 19(3):402-11. PubMed ID: 25560380
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Drug-eluting stents. The third revolution in percutaneous coronary intervention.
    Saia F; Marzocchi A; Serruys PW
    Ital Heart J; 2005 Apr; 6(4):289-303. PubMed ID: 15902927
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Propensity-matched lesion-based comparison of midterm outcomes of TAXUS Express and TAXUS Liberté stents for de novo native coronary stenosis.
    Ishikawa T; Nakano Y; Hino S; Suzuki T; Murakami A; Tsutsumi J; Miyamoto T; Mutoh M
    J Cardiol; 2013 Nov; 62(5):289-95. PubMed ID: 23806548
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of insulin-treated diabetes and hemodialysis on long-term clinical outcomes following sirolimus-eluting stent deployment. Insights from a sub-study of the Cypher Stent Japan Post-Marketing Surveillance(Cypher J-PMS) Registry.
    Nakamura M; Yokoi H; Hamazaki Y; Watarai M; Kijima M; Mitsudo K;
    Circ J; 2010 Nov; 74(12):2592-7. PubMed ID: 21041974
    [TBL] [Abstract][Full Text] [Related]  

  • 56. First clinical comparison of Nobori -Biolimus A9 eluting stents with Cypher- Sirolimus eluting stents: Nobori Core nine months angiographic and one year clinical outcomes.
    Ostojic M; Sagic D; Beleslin B; Jung R; Perisic Z; Jagic N; Nedeljkovic M; Mangovski L; Milosavljevic B; Stojkovic S; Orlic D; Antonic Z; Miloradovic V; Topic D; Paunovic D
    EuroIntervention; 2008 Mar; 3(5):574-9. PubMed ID: 19608483
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sirolimus- versus paclitaxel-eluting stents: numero uno, first among equals or equal?
    Kuchulakanti PK; Waksman R
    Future Cardiol; 2006 Jul; 2(4):483-91. PubMed ID: 19804183
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety and efficacy of multiple, overlapping polymer-based paclitaxel-eluting stents.
    Dawkins KD; Grube E; Guagliumi G; Banning AP; Zmudka K; Colombo A; Thuesen L; Hauptman K; Marco J; Wijns W; Popma JJ; Weissman NJ; Koglin J; Russell ME
    EuroIntervention; 2007 Aug; 3(2):213-21. PubMed ID: 19758940
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Utility of drug-eluting stents in complex lesions and high-risk patients.
    Nikolsky E; Stone GW
    Curr Treat Options Cardiovasc Med; 2007 Feb; 9(1):11-28. PubMed ID: 17378972
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Widowmaker Right Coronary Artery Treated With Drug-Eluting Stent Implantation.
    Singh G; Schreiter NA; Schreiter SW
    JACC Case Rep; 2019 Oct; 1(3):421-423. PubMed ID: 34316843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.